Trials / Completed
CompletedNCT00046787
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OSI-211 (Liposomal Lurtotecan) |
Timeline
- Start date
- 2002-09-01
- Completion
- 2003-02-01
- First posted
- 2002-10-04
- Last updated
- 2011-10-20
Locations
10 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00046787. Inclusion in this directory is not an endorsement.